XML 26 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Quarterly Financial Information (Unaudited) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2011
Revenues:                      
License and milestone fees $ 855 $ 22,010 $ 429 $ 933 $ 950 $ 999 $ 6,025 $ 1,187 $ 24,227 $ 9,161 $ 6,393
Research and development support 2,203 2,257 2,036 1,377 1,184 1,320 945 1,068 7,873 4,517 7,256
Clinical materials revenue 181 734 147 1,781 818 933 647 281 2,843 2,679 5,656
Royalty revenue 592               592    
Total revenues 3,831 25,001 2,612 4,091 2,952 3,252 7,617 2,536 35,535 16,357 19,305
Expenses:                      
Research and development 20,399 21,318 21,656 23,700 19,539 16,933 15,559 17,161 87,073 69,192 63,453
General and administrative 5,373 4,995 5,464 5,639 5,726 5,021 4,834 4,841 21,471 20,422 16,040
Total operating expenses 25,772 26,313 27,120 29,339 25,265 21,954 20,393 22,002 108,544 89,614 79,493
Loss from operations (21,941) (1,312) (24,508) (25,248) (22,313) (18,702) (12,776) (19,466) (73,009) (73,257) (60,188)
Other income (expense), net 66 (39) 115 56 (101) 33 23 (17)      
Net loss $ (21,875) $ (1,351) $ (24,393) $ (25,192) $ (22,414) $ (18,669) $ (12,753) $ (19,483) $ (72,811) $ (73,319) $ (58,274)
Basic and diluted net loss per common share (in dollars per share) $ (0.26) $ (0.02) $ (0.29) $ (0.30) $ (0.29) $ (0.24) $ (0.17) $ (0.26) $ (0.87) $ (0.95) $ (0.85)